Webcast

Recent JCP Articles on Webcast

Webcast

Pharmacotherapies for Early-Stage Alzheimer Disease

May 25, 2021

How do investigational drugs for Alzheimer disease differ from those currently prescribed to patients? Dr Burke shares her insights.

Anna D. Burke

Webcast

Discussing Early-Stage AD With Patients

May 11, 2021

In this webcast about early-stage Alzheimer disease, Drs Burke and Apostolova highlight important conversations to have with patients and their care partners on topics such as diet, exercise, driving,...

Anna D. Burke, Liana Apostolova

Webcast

Assessment for Alzheimer Disease

May 4, 2021

What are the steps for diagnosing Alzheimer disease? Are you familiar with diagnostic criteria and assessment tools? In this webcast, walk through the process with an expert.

Liana Apostolova

Featured Webcast Research

cTBS Over Right DLPFC in Insomnia Disorder

Original Research

cTBS Over Right DLPFC in Insomnia Disorder

November 12, 2026

This study evaluated the efficacy and safety of an intensive 21-session cTBS protocol targeting the rDLPFC in adults with insomnia disorder, using a double-blind randomized sham-controlled design with 3...

Neetu Garg, Shobit Garg, Mohan Dhyani

Medical Traumatic Stress and Medical Posttraumatic Stress Disorder Following Illness and Treatment: What Primary Care Providers Need to Know

Rounds in the General Hospital

Medical Traumatic Stress and Medical Posttraumatic Stress Disorder Following Illness and Treatment: What Primary Care Providers Need to Know

November 12, 2026

Medical PTSD has been associated with debilitating mental health symptoms and a decreased quality of life, as well as with worse medical outcomes.

Matthew Gunther, Alejandra E. Morfin Rodriguez, Mariella Suleiman, et al

DT120 for Generalized Anxiety Disorder: Findings From Phase 2b and Phase III Trials

Expert Commentary

DT120 for Generalized Anxiety Disorder: Findings From Phase 2b and Phase III Trials

November 11, 2026

Lori Davis, MD, reviews clinical trial findings on DT120, an oral disintegrating tablet formulation of lysergide, for generalized anxiety disorder. She describes efficacy findings across a phase 2b trial...